Cancer pharmacology : an illustrated manual of anticancer drugs / editors, Ashkan Emadi, Judith E. Karp
"We are living in an exciting time for cancer pharmacology. The fusion of multiple disciplines of basic and clinical science is creating effective, life-prolonging therapies for a growing number of malignancies. The progress is electrifying and the promise for patients is exhilarating!"--.
| Medienart: |
Buch |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
New York, NY: Springer Publishing Company ; 2024 |
| Ausgabe: |
Second edition |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Emadi, Ashkan [HerausgeberIn] |
|---|
| ISBN: |
|---|
| Nlm: |
QV 269 |
|---|---|
| Themen: |
| Anmerkungen: |
Includes bibliographical references and index |
|---|
| Umfang: |
xvi, 454 Seiten ; Illustrationen, Diagramme, Karten |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
1843004577 |
|---|
| LEADER | 01000cam a22002658 4500 | ||
|---|---|---|---|
| 001 | 1843004577 | ||
| 003 | DE-627 | ||
| 005 | 20240424143431.0 | ||
| 007 | tu | ||
| 008 | 230418s2024 xxu||||| 00| ||eng c | ||
| 020 | |a 9780826149329 |c paperback |9 978-0-8261-4932-9 | ||
| 035 | |a (DE-627)1843004577 | ||
| 035 | |a (DE-599)KXP1843004577 | ||
| 040 | |a DE-627 |b eng |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 044 | |c XD-US | ||
| 060 | 0 | |a QV 269 | |
| 245 | 1 | 0 | |a Cancer pharmacology |b an illustrated manual of anticancer drugs |c editors, Ashkan Emadi, Judith E. Karp |
| 250 | |a Second edition | ||
| 263 | |a 2306 | ||
| 264 | 1 | |a New York, NY |b Springer Publishing Company |c 2024 | |
| 300 | |a xvi, 454 Seiten |b Illustrationen, Diagramme, Karten | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Includes bibliographical references and index | ||
| 505 | 8 | 0 | |a Anticancer Drug Development : An Introduction / Edward A. Sausville -- Pharmacogenomics / Milly Graveno -- Critical Components of Clinical Trials Development : From Bench to Bedside and Back / S. Percy Ivy, Richard F. Little, and Joshua F. Zeidner -- Drug Development and Regulatory Considerations / Vicky Hsu, Matthew D. Thompson, Donna Przepiorka, and Olanrewaju O. Okusanya -- Alkylating Agents / Ashkan Emadi and Edward A. Sausville -- Pyrimidine- and Purine-based Antimetabolites, Hydroxyurea, Asparaginases / Ashkan Emadi and Judith E. Karp -- Antimetabolites : Antifolates / Justin Lawson -- Antimitotics / Edward A. Sausville and Ashkan Emadi -- DNA Repair, Apoptotic Pathways, and CDK Inhibitors / Mira A. Kohorst and Scott H. Kaufmann -- Epigenetic Modulators / Sergiu Pasca and Lukasz P. Gondek -- Differentiating Agents and Microenvironment / Yuya Nagai and Gabriel Ghiaur -- Targeted Therapeutics (Small Molecules) / Yuchen (Jake) Liu and Ashkan Emadi -- Hormonal Therapies Alone and in Combinations for Treatment of Breast Cancer / Amy M. Fulton and Katherine H. R. Tkaczu -- Androgen Receptor Axis Targeting in the Treatment of Prostate Cancer / Vincent C. O. Njar and Arif Hussain -- Multiple Myeloma as a Paradigm for MultiTargeted Intervention / Kathryn Maples and Sagar Lonial -- Transplant-Related Agents : Focus on Graft vs. Host Disease Prevention and Treatment / Vedran Radojcic -- Monoclonal Antibodies Including Immunoconjugates, Antibody-Drug Conjugates, and Cytokine-Directed Agents / Alison Duffy and Ciera -- Bernhardi -- Immunotherapeutics : Checkpoint Inhibitors, Vaccines, Bispecifics, and CAR-T / Mark Yarchoan and Elizabeth Jaffee. |
| 520 | |a "We are living in an exciting time for cancer pharmacology. The fusion of multiple disciplines of basic and clinical science is creating effective, life-prolonging therapies for a growing number of malignancies. The progress is electrifying and the promise for patients is exhilarating!"-- | ||
| 650 | 2 | |a Antineoplastic Agents |x pharmacology | |
| 650 | 2 | |a Neoplasms |x drug therapy | |
| 650 | 2 | |a Molecular Targeted Therapy | |
| 700 | 1 | |a Emadi, Ashkan |e herausgeberin |4 edt | |
| 700 | 1 | |a Karp, Judith E. |e herausgeberin |4 edt | |
| 776 | 1 | |z 9780826149336 |c ebook | |
| 776 | 0 | 8 | |i Erscheint auch als |n Online-Ausgabe |t Cancer pharmacology |b Second edition |d New York, NY : Springer Publishing Company, [2024] |z 9780826149336 |
| 912 | |a GBV_ILN_20 | ||
| 912 | |a ISIL_DE-84 | ||
| 912 | |a SYSFLAG_1 | ||
| 912 | |a GBV_KXP | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a SSG-OPC-DE-84 | ||
| 912 | |a GBV_ILN_120 | ||
| 912 | |a ISIL_DE-715 | ||
| 951 | |a BO | ||
| 980 | |2 20 |1 01 |x 0084 |b 4484662523 |c 00 |f MAG |d 2973-7082*KAT* |e --%%-- |j --%%-- |y k |z 24-04-24 | ||
| 980 | |2 120 |1 01 |x 0715 |b 4311110626 |c 00 |f --%%-- |d --%%-- |e g |j --%%-- |h alma |y z |z 19-04-23 | ||
| 984 | |2 20 |1 01 |x 0084 |a 84$200015303 | ||
| 984 | |2 120 |1 01 |x 0715 |a b30227864 | ||
| 995 | |2 120 |1 01 |x 0715 |a alma | ||